Adaptimmune Reports Better Outcomes For People With Synovial Sarcoma Who Received Afami-cel Compared To Historical Control
Portfolio Pulse from Benzinga Newsdesk
Adaptimmune Therapeutics (NASDAQ:ADAP) has reported positive outcomes for patients with synovial sarcoma who received afami-cel in the SPEARHEAD-1 trial. The trial showed a 39% clinical response rate with a median duration of response of 12 months. The median overall survival was 17 months, compared to a historical median of less than 12 months for patients who received two or more prior lines of therapy. Adaptimmune is on track to make afami-cel its first commercial product, with the completion of the Biologics License Application (BLA) targeted for Q4 2023.
October 31, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adaptimmune's positive trial results for afami-cel could potentially lead to its first commercial product, which may boost investor confidence and potentially the company's stock price.
The positive trial results for afami-cel indicate that Adaptimmune is making significant progress in its product development. This could potentially lead to the commercialization of afami-cel, which would be a significant milestone for the company and could attract investor interest, potentially leading to an increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100